Small molecule modulation of 14-3-3 protein-protein interactions
14-3-3 蛋白质-蛋白质相互作用的小分子调节
基本信息
- 批准号:10607941
- 负责人:
- 金额:$ 6.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAffectAffinityAlder plantAntineoplastic AgentsApoptosisBindingBiologicalBiologyCancer ControlCancer cell lineCell Cycle ProgressionCell physiologyChemicalsCollaborationsComplexCrystallographyDataDevelopmentDrug resistanceFamilyFosteringGluesGoalsInstitutionInvestigationKnowledgeMalignant NeoplasmsModificationMolecularNatural ProductsNatural SourceNormal CellOncogenicOrganic SynthesisPathway interactionsPharmaceutical ChemistryPharmaceutical PreparationsPositioning AttributeProcessProteinsProteomicsReactionResearchResistanceRoleRouteSignal TransductionSiteSpecificityStructureStructure-Activity RelationshipSynthesis ChemistryTherapeuticTrainingWorkanaloganti-canceranticancer activitycancer cellcancer therapychemical synthesisdesignimprovedinsightinterestnovelpreventprotein protein interactionsmall moleculestandard of caretherapeutic candidatetherapeutic developmenttumorigenic
项目摘要
PROJECT SUMMARY
14-3-3 proteins are at the crossroads of diverse cellular processes relevant to cancer, such as signal
transduction, cell cycle progression and apoptosis. This family of hub proteins regulates these functions through
an expansive network of protein-protein interactions (PPIs) that constitute the 14-3-3 “interactome.” Small
molecule modulation of the 14-3-3 interactome is therefore of significant interest for cancer treatment, especially
given the role of 14-3-3 proteins in resistance to standard of care drugs. Drugging the 14-3-3 signaling hub also
enables multiple cancer-relevant processes to be perturbed in concert. Although modulation of 14-3-3 PPIs
remains underdeveloped, the natural product cotylenin A presents a molecular platform to address this
deficiency. Cotylenin A stabilizes 14-3-3/partner interactions by functioning as a rare “molecular glue.” This is
believed to underlie cotylenin A’s notable anticancer activity and ability to sensitize cancer cells to existing
treatments while sparing normal cells. Additionally, cotylenin A’s uncommon binding mode carries advantages
of improved drug selectivity and lower affinities required for efficacy. However, cotylenin A has not been
developed as a therapeutic due to loss of natural sources and lack of efficient and readily diversifiable syntheses.
This proposal seeks to invigorate the development of cotylenin-based cancer therapies through chemical
synthesis. Leveraging our group’s expertise in organic synthesis, we will develop an efficient and modular route
to cotylenin A. Proof of concept for this synthetic strategy to access the cotylenin core has already been
established, and will facilitate completion of the cotylenin A synthesis. The cotylenin core will enable immediate
diversification at several positions to generate analogues based on existing crystallographic data. Modification
of the synthesis at early stages will also allow structure-based diversification at additional sites, including one
that provides a novel means to achieve specificity in PPI modulation. The anticancer activity of the analogues
will be evaluated to elucidate structure-activity relationships. We will also conduct proteomic studies to identify
the affected protein targets. This knowledge will guide iterative medicinal chemistry optimization of cotylenins.
Research will be carried out at Scripps Research, an institution that excels in synthetic chemistry and chemical
biology, and fosters strong collaboration across the two fields. I will receive training in complex molecule
synthesis from Prof. Ryan Shenvi, a leader in the field, as well as training in chemical biology by performing
biological and proteomic studies in collaboration with Prof. Chris Parker at Scripps Research. This work is
complimentary to my doctoral training in the study of organometallic reaction mechanisms.
项目总结
14-3-3蛋白处于与癌症相关的不同细胞过程的十字路口,例如信号
转导、细胞周期进程和细胞凋亡。这个中枢蛋白家族通过以下途径调节这些功能
构成14-3-3“相互作用体”的蛋白质-蛋白质相互作用(PPI)的扩展网络。小的
因此,14-3-3相互作用体的分子调控在癌症治疗中具有重要意义,尤其是
鉴于14-3-3蛋白在标准护理药物耐药中的作用。给14-3-3信号集线器下药也
使多个与癌症相关的过程受到干扰。虽然14-3-3 PPI的调制
仍然不发达,天然产物子叶素A提供了一个解决这一问题的分子平台
缺乏症。Cotylenin A作为一种罕见的“分子胶”,稳定了14-3-3/伴侣之间的相互作用。这是
据信是胚胎素A显著的抗癌活性和使癌细胞对现有
治疗的同时保留正常细胞。此外,胚胎素A不同寻常的结合模式具有优势
提高了药物选择性,降低了疗效所需的亲和力。然而,胚轴蛋白A还没有被
由于自然资源的丧失和缺乏有效和易于多样化的合成,开发成一种治疗药物。
这项提案旨在通过化学方法促进以胚轴为基础的癌症疗法的发展。
综合。利用我们集团在有机合成方面的专业知识,我们将开发一条高效和模块化的路线
到胚轴蛋白A。这种接近胚轴蛋白核心的合成策略的概念证明已经
建立,并将促进完成子叶素A的合成。胚轴蛋白核心将使立即
在几个位置多样化,以现有的结晶学数据为基础产生类似物。改型
在早期阶段的综合还将允许在更多地点进行基于结构的多样化,包括一个
这为实现PPI调节的特异性提供了一种新的手段。类似物的抗癌活性
将进行评估,以阐明结构-活性关系。我们还将进行蛋白质组学研究,以确定
受影响的蛋白质靶标。这些知识将指导子叶素的迭代药物化学优化。
研究将在斯克里普斯研究公司进行,这是一家在合成化学和化学方面表现出色的机构
生物学,并促进这两个领域的强大合作。我将接受复杂分子方面的培训
该领域的领军人物瑞安·申维教授的合成,以及通过执行
与斯克里普斯研究中心的克里斯·帕克教授合作进行生物学和蛋白质组学研究。这项工作是
这是对我在研究有机金属反应机理方面的博士培训的补充。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen I Ting其他文献
Stephen I Ting的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 6.87万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 6.87万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 6.87万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 6.87万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 6.87万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 6.87万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 6.87万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 6.87万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 6.87万 - 项目类别: